Genentech/Biogen Idec Submit Rituxan sBLA For Rheumatoid Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
Filing is second in two weeks for the biologic, following recent sBLA submission for front-line non-Hodgkin's lymphoma treatment.